LOGIN  |  REGISTER

Alnylam Pharmaceuticals (NASDAQ: ALNY) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$173.85 -1.67 -0.95
Volume: 674,376
5-Day Change: -17.86%
YTD Change: -26.85%
Market Cap: US$21.730B

Latest News From Alnylam Pharmaceuticals

September 13, 2023
Alnylam Pharmaceuticals Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Prescription Drug User Fee Act Target Action Date is October 8, 2023 CAMBRIDGE, Mass. / Sep 13, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the positive outcome of the U.S. Food... Read More
September 13, 2023
Alnylam Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
CAMBRIDGE, Mass. / Sep 13, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee is meeting today to review the supplemental New Drug Application for patisiran, an investigational RNAi therapeutic in... Read More
September 7, 2023
Alnylam Pharmaceuticals Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Zilebesiran Met Primary Endpoint Demonstrating Greater than 15 mmHg Reduction of Systolic Blood Pressure at Three Months of Treatment Compared to Placebo at Two Highest Single Doses Evaluated Study Met Key Secondary Endpoints Showing Consistent and Sustained Reductions of Systolic Blood Pressure at Six Months, Supporting Quarterly or Biannual Dosing Zilebesiran Demonstrated an Encouraging Safety and Tolerability Profile in... Read More
August 25, 2023
Alnylam Pharmaceuticals to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
CAMBRIDGE, Mass. / Aug 25, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an update on its ongoing patent infringement litigation. On March 17, 2022, Alnylam initiated litigation in the United States District Court for the District of Delaware against Moderna for patent infringement. To date, in two separate actions against Moderna, Alnylam has... Read More
August 3, 2023
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
Achieved Second Quarter 2023 Global Net Product Revenues of $306 Million, Representing 43% Year-Over-Year Growth Compared to Q2 2022 Submitted 18-Month APOLLO-B Data to the U.S. Food and Drug Administration as Amendment to Supplemental New Drug Application for Patisiran Presented Updated Positive Interim Results from Phase 1 Study of ALN-APP in Patients with Early-Onset Alzheimer’s Disease Entered into Global Strategic... Read More
August 2, 2023
Alnylam Pharmaceuticals to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
CAMBRIDGE, Mass. / Aug 02, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 43 rd Annual Growth Conference on Thursday, August 10, 2023 at 10:30 am ET at the InterContinental Hotel in Boston. A live audio webcast of the presentation will be available on the Investors section of... Read More
July 24, 2023
Alnylam Pharmaceuticals Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Partnership Combines Alnylam’s Leadership in RNAi Therapeutics with Roche’s Proven Track Record of Successfully Developing and Launching Innovative Medicines Worldwide Zilebesiran Represents a Potentially Transformative Approach to Reducing CV Morbidity and Mortality in Hypertension Patients at High CV Risk by Robustly and Durably Lowering Blood Pressure Alnylam will Receive an Upfront Cash Payment of $310 Million and is... Read More
July 20, 2023
Alnylam Pharmaceuticals to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
CAMBRIDGE, Mass. / Jul 20, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2023 on Thursday, August 3, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2023 results as well as expectations for the... Read More
July 19, 2023
Alnylam Pharmaceuticals Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
Dose-Dependent Reductions in Serum Angiotensinogen and 24-hour Ambulatory Blood Pressure Were Sustained for Six Months After Single Doses of Zilebesiran Acceptable Safety Profile Supporting Further Development CAMBRIDGE, Mass. / Jul 19, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from its Phase 1 study of zilebesiran, an... Read More
July 17, 2023
Alnylam Pharmaceuticals Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
First Clinical Study of a Central Nervous System-Administered RNAi Therapeutic Showed Rapid and Robust Target Engagement with Sustained Effect Over 6 Months with a Single Dose ALN-APP Continues to Demonstrate an Encouraging Clinical Safety and Tolerability Profile Multiple-dose Portion of Study, Part B, Being Initiated in Approved Regions CAMBRIDGE, Mass. / Jul 17, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc.... Read More
June 30, 2023
Alnylam Pharmaceuticals Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
CAMBRIDGE, Mass. / Jun 30, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an investigational treatment for the cardiomyopathy of... Read More
June 5, 2023
Alnylam Pharmaceuticals to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
CAMBRIDGE, Mass. / Jun 05, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:00 am PT (11:00 am ET) at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. A live audio webcast of the presentation... Read More
May 20, 2023
Alnylam Pharmaceuticals Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as Cardiac Stress and Injury, through 18 Months Safety Profile Consistent with that Observed in 12-Month Double-Blind Period, with No New Safety Findings CAMBRIDGE, Mass. / May 20, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc.... Read More
May 4, 2023
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 Reported Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy, Establishing First-Ever Human Translation of RNAi Therapeutics in CNS Reiterated 2023 Financial Guidance, Including Combined Net Product... Read More
May 3, 2023
Alnylam Pharmaceuticals to Webcast Presentation at BofA Securities 2023 Health Care Conference
CAMBRIDGE, Mass. / May 03, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 1:40 pm PT (4:40 pm ET) at the Encore Hotel in Las Vegas. A live audio webcast of the presentation will be available on the Investors section of the... Read More
May 3, 2023
Alnylam Pharmaceuticals Issues 2022 Corporate Responsibility Report
Successfully Met Goals Outlined in MassBio’s Diversity, Equity, and Inclusion (DE&I) Industry Pledge New Disclosures of Company’s Impact on Planet—Including Multiyear Data on Scope 1, Scope 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions CAMBRIDGE, Mass. / May 03, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility... Read More
April 26, 2023
Alnylam Pharmaceuticals and Regeneron Pharmaceuticals Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the Human Brain Using Alnylam's Proprietary C16 Platform Alnylam to Host Conference Call Today... Read More
April 20, 2023
Alnylam Pharmaceuticals to Webcast Conference Call Discussing First Quarter 2023 Financial Results
CAMBRIDGE, Mass. / Apr 20, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2023 results as well as expectations for the future... Read More
March 9, 2023
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
ZUG, Switzerland , March 9, 2023 /CNW/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary , Slovakia ,... Read More
March 8, 2023
Alnylam Pharmaceuticals Announces Appointment of Peter Kellogg to Board of Directors
CAMBRIDGE, Mass. / Mar 08, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. “Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to... Read More
February 23, 2023
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
CAMBRIDGE, Mass. / Feb 23, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights. “2022 was another year of strong progress at Alnylam, including our continued commercial execution which delivered 35% full-year product... Read More
February 21, 2023
Alnylam Pharmaceuticals Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
CAMBRIDGE, Mass. / Feb 21, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR)... Read More
February 2, 2023
Alnylam Pharmaceuticals to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
CAMBRIDGE, Mass. / Feb 02, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2022 results as well... Read More
January 8, 2023
Alnylam Pharmaceuticals Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO ® , AMVUTTRA ® , GIVLAARI ® , and OXLUMO ® , Representing 35% Annual Growth (43% Using Constant Exchange Rate**) Strength of AMVUTTRA Launch Drove 37% Total TTR Annual Revenue Growth – Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of Approximately $2.2 Billion Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),... Read More
January 5, 2023
Alnylam Pharmaceuticals Announces Updates to its Board of Directors
Appoints Carolyn Bertozzi, Ph.D., Nobel Laureate and Leading Voice for Chemical Biology, Emerging Technology, and Life Sciences Companies Michael W. Bonney Steps Down as Executive Chair and Continues on Board as Non-Independent Director Amy W. Schulman will Assume Role of Chair of the Board Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, today announces appointment of Carolyn Bertozzi,... Read More
January 3, 2023
Alnylam Pharmaceuticals to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter and full year 2022... Read More
December 21, 2022
Alnylam Pharmaceuticals Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting... Read More
December 8, 2022
Alnylam Pharmaceuticals Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 Study Also Demonstrated Encouraging Safety Profile in Patients with Cardiomyopathy of ATTR Amyloidosis CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi... Read More
Surmodics

COPYRIGHT ©2023 HEALTH STOCKS HUB

  Research Tools
  News & Announcements
  Popular Topics
  Miscellaneous